Genfit
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France. Show More...
-
Website https://www.genfit.com
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 4.51 USD
-
Last Updated 30-05-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2009-12 2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 TTM Earnings Per Share EUR -0.63 -0.79 -0.75 -0.35 -0.63 -0.74 -0.69 -1.25 -1.79 -2.55 -3.01 Dividends EUR Payout Ratio % * Shares Mil 12.0 12.0 13.0 15.0 20.0 23.0 25.0 27.0 31.0 31.0 39.0 Book Value Per Share * USD 2.36 Free Cash Flow Per Share * USD Return on Assets % -17.47 -26.87 -32.03 -20.55 -47.99 -29.48 -22.02 -28.6 -25.51 -30.43 -32.0 Financial Leverage (Average) 2.47 3.74 6.52 3.45 2.07 1.23 1.25 1.16 2.81 10.96 3.37 Return on Equity % -38.91 -78.47 -150.74 -95.86 -120.92 -40.29 -27.23 -33.97 -47.45 -127.06 -113.2 Return on Invested Capital % -25.16 -60.17 -150.22 -32.08 -65.15 -34.45 -25.48 -32.17 -27.79 -30.01 -32.43 Interest Coverage -13.81 -19.04 -19.93 -31.42 -99.23 -180.7 -304.73 -40.85 -6.28 -6.47 Current Ratio 2.5 1.67 1.31 2.99 8.07 7.75 9.22 10.46 5.56 6.45 Quick Ratio 1.83 1.19 1.21 2.85 7.96 7.68 9.15 10.4 5.5 6.38 Debt/Equity 0.44 1.11 0.39 0.07 0.08 0.04 1.54 7.95 1.85